ARTICLE | Clinical News
Autologous T cell therapy against CD19 regulatory update
August 22, 2016 7:00 AM UTC
EMA granted PRIority MEdicines (PRIME) designation to KTE-C19 from Kite to treat refractory diffuse large B cell lymphoma (DLBCL). KTE-C19 comprises autologous T cells genetically modified to express ...